Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 12,310 | 12,748 | 11,571 | 10,254 | 7,599 |
| Cost of Goods | 3,814 | 4,045 | 3,721 | 3,395 | 2,653 |
| Gross Profit | 8,496 | 8,703 | 7,850 | 6,859 | 4,946 |
| Operating Expenses | 45,461 | 54,628 | 52,904 | 52,740 | 51,034 |
| Operating Income | -36,151 | -45,880 | -44,333 | -45,486 | -45,435 |
| Interest Expense | 2,186 | 2,249 | 2,325 | 2,277 | 2,150 |
| Other Income | 1,402 | 1,782 | 2,141 | 2,901 | 187 |
| Pre-tax Income | -36,935 | -46,347 | -44,517 | -44,862 | -47,398 |
| Net Income Continuous | -36,935 | -46,347 | -44,517 | -44,862 | -47,398 |
| Net Income Discontinuous | -1,392 | 8,704 | 8,986 | 342,629 | -9,171 |
| Net Income | $-38,327 | $-37,643 | $-35,531 | $297,767 | $-56,569 |
| EPS Basic Total Ops | -0.28 | -0.34 | -0.31 | 2.57 | -0.49 |
| EPS Basic Continuous Ops | -0.27 | -0.38 | -0.38 | -0.39 | -0.41 |
| EPS Basic Discontinuous Ops | -0.01 | 0.05 | 0.08 | 2.95 | -0.08 |
| EPS Diluted Total Ops | -0.28 | -0.34 | -0.31 | 2.57 | -0.49 |
| EPS Diluted Continuous Ops | -0.27 | -0.38 | -0.38 | -0.39 | -0.41 |
| EPS Diluted Discontinuous Ops | -0.01 | 0.05 | 0.08 | 2.95 | -0.08 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.39 | -0.38 | -0.39 | -0.41 |
| EBITDA(a) | $-35,270 | $-44,984 | $-43,367 | $-44,470 | $-44,389 |